^
Association details:
| Biomarker: | RNASE7 expression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5286 - RNase7-guided anti-ROS1 targeted therapy for hepatocellular carcinoma
Published date:
03/09/2022
Excerpt:
In HCC patient-derived xenograft and an orthotopic mouse model of HCC, we found that crizotinib, an FDA-approved ROS1 inhibitor, exhibits potent anti-tumor activity in the mice harboring RNase7-expressing tumors.